MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

CCT128930

CAS No. : 885499-61-6

MCE 站：CCT128930

产品活性：CCT128930 是一种有效的选择性 Akt2 抑制剂 (IC₅₀ 为 6 nM)，比作用于 PKA 激酶 (IC₅₀ 为 168 nM) 选择性高 28 倍，比作用于 p70S6K (IC₅₀ 为 120 nM) 选择性高 20 倍。

研究领域：PI3K/Akt/mTOR  |  Autophagy

作用靶点：Akt  |  Autophagy

In Vitro: CCT128930 exhibits marked antiproliferative activity and inhibits the phosphorylation of a range of Akt substrates in multiple tumor cell lines in vitro, consistent with Akt inhibition. CCT128930 causes a G1 arrest in PTEN-null U87MG human glioblastoma cells, consistent with Akt pathway blockade. CCT128930 is a potent ATP-competitive Akt inhibitor, which is initially screened at 10 ?M against a panel of kinases representative of the human protein kinome. In view of the potential of ATP-competitive inhibitors to cross-react with the closely related AGC class of kinases, the IC₅₀ of CCT128930 against selected AGC kinases is determined. The GI₅₀ values of CCT128930 for growth inhibition are 6.3 μM±2.2 (n=3) for U87MG human glioblastoma cells, 0.35 μM±0.11 (n=4) for LNCaP human prostate cancer cells, and 1.9 μM±0.80 (n=5) for PC3 human prostate cancer cells, all of which are PTEN-deficient human tumor cell lines.

In Vivo: The pharmacokinetics of CCT128930 after a single dose of 25 mg/kg are shown. Following i.v. administration, CCT128930 reaches a peak concentration of 6.4 ?M in plasma and is eliminated with a relatively short half-life, high volume of distribution and rapid clearance, giving an AUC_0-∞ of 4.6 ?Mh. Following i.p. administration, the peak plasma drug concentration is 4-fold lower and the plasma clearance is similar to that observed i.v..The corresponding AUC_0-∞ is 1.3 ?Mh, giving an i.p. bioavailability of 29%.

相关产品：Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  PI3K/Akt/mTOR Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Differentiation Inducing Compound Library  |  Oxygen Sensing Compound Library  |  Glycolysis Compound Library  |  Cytoskeleton Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Honokiol  |  GSK-690693  |  Artemisinin  |  Oridonin  |  Perifosine  |  Guggulsterone  |  Miransertib  |  Triciribine  |  Recilisib  |  SU6656  |  Isobavachalcone  |  Scutellarin  |  Deguelin  |  Miltefosine  |  A-674563 hydrochloride  |  α-Linolenic acid  |  YS-49  |  Urolithin B  |  Polyphyllin I  |  Pachymic acid  |  3CAI  |  1,3-Dicaffeoylquinic acid  |  Esculetin  |  Cyclovirobuxine D  |  Licochalcone E  |  SC66  |  Akt1 and Akt2-IN-1  |  Arnicolide D  |  Loureirin A

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。